Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 311 of 5804
-
Gut bacteria clues could lead to simple cancer test
Diagnosis Recruiting nowColorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally, with increasing incidence rates. While predominantly affecting older adults, CRC cases among individuals under 50 (early-onset CRC, or EoCRC) are rising. This age group rarely undergoes routin…
Sponsor: Gulbenkian Institute for Molecular Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Sharper radiation beams aim to improve prostate cancer outcomes
Disease control Recruiting nowThe aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This …
Phase: NA • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Virus and chemo combo takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Phase: PHASE1, PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New shot could help sleep apnea patients breathe easier and shed pounds
Disease control Recruiting nowThe aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
Phase: PHASE3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
AI spots hidden heart valve disease in routine scans
Diagnosis Recruiting nowThis is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans. The primary objective is to evaluate the model's diagnostic performance, with the sensitivi…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
New hope for tough leukemia: experimental therapy CT1390B enters first human tests
Disease control Not yet recruitingA Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for Hard-to-Treat prostate cancer: Drug-Radiation combo trial launches
Disease control Recruiting nowThe aim of this study is to evaluate the efficacy of SHR-1701 in combination with SBRT in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Engineered immune cells take on stomach cancer in early trial
Disease control Recruiting nowThis example planning study proposes a phase 1/2 evaluation of an allogeneic, cord-blood-derived dual-target CAR-NK product directed against CLDN18.2 and HER2 (ERBB2) in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma after prior standar…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Off-the-Shelf cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowstudy evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy. The primary goals are to assess safety and tolerability, …
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental combo targets Hard-to-Treat colorectal liver metastases
Disease control Not yet recruitingAn open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo aims to bridge blood cancer patients to Life-Saving transplant
Disease control Recruiting nowThis phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritin…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Freeze and unleash: experimental combo aims to boost immune attack on aggressive breast cancer
Disease control Not yet recruitingSummary Points: 1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure. Newer innovative treatment strategies are needed to improve systemic control of disease and survival. 2. Immune system modulation: is an em…
Phase: PHASE1, PHASE2 • Sponsor: Texas Tech University Health Sciences Center • Aim: Disease control
Last updated Jun 26, 2026 15:10 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is: • Whether the efficacy and safety of QL1207H and aflibercept…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail aims to stop cervical cancer return
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy. It will also learn about the safety of the combination of Pembroliz…
Phase: PHASE2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a simple vitamin boost plaque stability and cut stroke risk?
Disease control Recruiting nowThis is a prospective, exploratory, cohort clinical study aiming to further investigate the direct impact of folic acid on the stability of carotid atherosclerotic plaques, building upon substantial clinical evidence confirming that folic acid supplementation reduces the risk of …
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
Diagnosis Not yet recruitingThis study is a single-center, single-arm, open-label exploratory study to evaluate the safety and efficacy of fluorescent imaging combined with a robotic surgical control system for robot-assisted radical prostatectomy.
Phase: PHASE2 • Sponsor: Zhu Yinjie • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Tumor avatars could personalize sarcoma therapy
Disease control ENROLLING_BY_INVITATIONThis study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma. The primary endpoint of the study is objective response rate (ORR). The s…
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Heart scar on MRI may decide who gets a lifesaving shock device
Disease control Not yet recruitingResearch questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate. Improved risk stratification is needed to select patients at highest risk. Hypotheses: 1. In…
Phase: NA • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Menopause makeover: study tests if lifestyle changes can reverse aging and cut disease risk
Disease control Recruiting nowWhat if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthie…
Phase: PHASE2, PHASE3 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC